BloomShield CIC
Technology development and research coordination
Africa · Proposed multinational research programme
A proposed collaborative research and implementation programme exploring how digital screening intelligence can strengthen referral navigation and continuity of care in Nigeria, Zimbabwe and Kenya.
Community implementation and clinical research
Research expansion and evaluation
Health-system validation and impact
The institutional relationships described here support research collaboration. The ACCEPT SIMS™ field-validation programme is proposed: participating sites, responsibilities, protocols, approvals and resources remain to be agreed. No award of funding is implied.
BloomShield’s ambition is to develop a locally led, multinational research programme that connects cervical screening information with referral navigation and continuity of care. ACCEPT SIMS™ could provide a shared research architecture while allowing each setting to retain its own priorities, clinical pathways and governance.
The proposed programme would explore feasibility and implementation across Nigeria, Zimbabwe and Kenya. Its purpose is to generate evidence about what works, for whom and under what conditions, before any wider adoption is considered.
A recorded screening result does not establish that a person received the result, reached a referral service or completed follow-up. The research ambition is to make these transitions visible and understand where people need support.
Proposed research would examine barriers such as transport, cost, communication and service availability alongside the experience of participants and care teams. Definitions of completion and resolution would be agreed with local clinical leadership.
The existing ACCEPT SIMS™ demonstrator explores a longitudinal screening registry, navigation information and future AI evaluation. It currently uses entirely synthetic participant records and is for research discussion and co-design.
Synthetic data can illustrate workflows and information structures. It cannot establish clinical accuracy, patient benefit, real-world usability, safety, fairness or effectiveness. The demonstrator is not a deployed clinical system, a validated AI system or a replacement for clinical judgement.
Any study using real participant data would need a separately agreed protocol, lawful data arrangements, appropriate consent, security controls and applicable ethics and regulatory approvals. Any AI evaluation would require its own defined model, reference standard and oversight.
The collaborative research framework brings together technology development, academic research, clinical evaluation and healthcare implementation capabilities. The relationships below inform programme development; participation in proposed ACCEPT SIMS™ field validation would require further institutional and local agreements.
Technology development and research coordination
Nigerian healthcare operations and proposed implementation
Nigerian academic research
Visit Bowen UniversityUniversity of Zimbabwe Clinical Trials Research Centre
Clinical research and evaluation
Visit University of Zimbabwe / UZ-CTRCCancer-control research and programme evaluation
Visit National Cancer Institute of KenyaOptimal Cancer Care Foundation and Lifecrown Foundation are also included in the wider partnership landscape. Their involvement in any ACCEPT SIMS™ study, including responsibilities and site-level arrangements, would be defined through further discussion and agreement.
Institutional roles describe the research relationships and proposed areas of contribution. They do not indicate an approved field trial, confirmed deployment or awarded funding.
These workstreams are proposals for co-design. Final scope, sites and leadership would be agreed with the relevant institutions and local teams.
Community implementation and clinical research
Co-design community recruitment, screening-to-referral workflows and navigation research with local clinical, academic and implementation teams. Explore how practical barriers and follow-up can be recorded in routine settings.
BOLSBOY’s own corporate digital-health partnership page showcases its collaboration with BloomShield CIC and ACCEPT SIMS™.
Research expansion and evaluation
Explore adaptation to local clinical research settings, evaluate data completeness and workflow feasibility, and develop locally relevant implementation and evaluation questions.
Health-system validation and impact
Explore alignment with cancer-control priorities, referral systems and programme evaluation. Assess what evidence would be needed to understand feasibility, equity and potential health-system impact.
A proposed staged, mixed-methods approach would begin with local pathway mapping and co-design. Feasibility work would precede any larger evaluation. Sample sizes, study duration, comparison methods and analysis plans remain to be specified in an agreed protocol.
Potential measures include referral completion, time to follow-up, unresolved pathways, acceptability and implementation cost. These are proposed research outcomes, not demonstrated benefits. If AI is included in a future protocol, model performance and clinician agreement would be evaluated separately from pathway outcomes.
Country teams and communities should help define the questions, implementation choices and interpretation of findings. Proposed capacity building would include shared training in pathway documentation, data quality, evaluation and responsible digital-health research.
The aim is useful, locally meaningful evidence that can inform decisions about adaptation and scale. Wider implementation would depend on the findings and on further agreements and approvals.
We welcome discussions with academic, clinical, cancer-control, community and implementation organisations interested in co-designing this research. Tell us about your setting, proposed contribution and the pathway questions that matter locally.
Partnership RequestsThe contact form will open with the African Research Partnerships enquiry category selected.